Logo Image
News|Podcasts|January 20, 2026

ACT Brief: Signal Durability Redefines RBQM, AI Targets Startup Friction, and CDMOs Advance Patient-Centric Formulation

In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management, how AI can reduce startup delays without burdening sites, and how patient-centric drug design is reshaping the CDMO landscape.

  • A new Applied Clinical Trials contributed analysis of more than 880 clinical trials shows that durability—not speed—is the key differentiator in effective signal management under risk-based quality frameworks. While statistical data monitoring and key risk indicator signals close on similar timelines, SDM signals are far less likely to be reopened. The findings reinforce growing regulatory expectations under ICH E6(R3) for defensible, evidence-based signal closure across the trial lifecycle.
  • In part 3 of a video interview with Applied Clinical Trials, Brian Mallon of ICON says AI and automation can help address persistent startup delays when applied to reduce administrative burden rather than add complexity. He points to contract tools that surface previously agreed language as practical examples of site-friendly innovation. Mallon emphasizes that operational technology must ultimately serve investigators and patients, preserving the human core of clinical research.
  • In a PharmTech Q&A, Dr. Asma Patel of Quotient Sciences says the rise of patient-centric drug formulations is driving greater reliance on CDMOs with specialized scientific and manufacturing capabilities. Patel explains that advanced modalities and personalized dosing needs are pushing CDMOs earlier into development, particularly for rare and orphan drugs. As a result, CDMOs are increasingly acting as strategic partners across formulation, scale-up, and regulatory readiness.

Related Content